Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Recruiting
Phase 4
Interventional Study
Hepatic Encephalopathy
Cirrhosis, Liver
Portal Hypertension
Liver Diseases
Pathological Processes
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 238 (estimated)
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or overt HE (OHE, grade II-IV). Liver cirrhosis is the most common cause of portal hypertension (PH). Patients who develop complications of PH, like variceal bleeding or refr…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Elective TIPS placement for refractory ascites or recurrent variceal bleeding:
Recurrent tense ascites and one or more of the following criteria:
i. Not responding to the maximal dose of diuretics (400 milligram spironolactone and 160 milligram furosemide).
ii. Ki…
Contacts